(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-3-(1,3-thiazol-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide | 1401249-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-3-(1,3-thiazol-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
• 英文别名: (5R,7S)-1-(3-fluorophenyl)-7-methyl-8-[(3-propan-2-yloxyphenyl)methyl]-3-(1,3-thiazol-2-yl)-2lambda6-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide；(5R,7S)-1-(3-fluorophenyl)-7-methyl-8-[(3-propan-2-yloxyphenyl)methyl]-3-(1,3-thiazol-2-yl)-2λ6-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
• CAS: 1401249-75-9
• 化学式: C₂₆H₃₁FN₄O₃S₂
• 分子量: 530.688
• InChiKey: HZDBHXACFJDRIT-RXFWQSSRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (5R,7S)-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide 在 copper(l) iodide 、 potassium carbonate 、 三乙胺 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 反应 0.5h， 生成 (5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-3-(1,3-thiazol-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
  参考文献：
  名称：

  Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

  摘要：

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.

  DOI：

  10.1021/jm3009426

文献信息

• Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors
  作者：Michael A. Brodney、Gabriela Barreiro、Kevin Ogilvie、Eva Hajos-Korcsok、John Murray、Felix Vajdos、Claude Ambroise、Curt Christoffersen、Katherine Fisher、Lorraine Lanyon、JianHua Liu、Charles E. Nolan、Jane M. Withka、Kris A. Borzilleri、Ivan Efremov、Christine E. Oborski、Alison Varghese、Brian T. O’Neill

  DOI：10.1021/jm3009426

  日期：2012.11.8

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.